The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy
Open Access
- 1 April 2020
- journal article
- research article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 26 (4), 361-366
- https://doi.org/10.18553/jmcp.2020.26.4.361
Abstract
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Kaiser Foundation Health Plan, and Partners HealthCare to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from Aetna, America’s Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Agboola, Fluetsch, Rind, and Pearson are employed by ICER. Lin reports support from ICER during work on this economic model and grants from Mount Zion Health Fund, National Institutes of Health (National Cancer Institute and National Heart, Lung, and Blood Institute), and the Tobacco-Related Diseases Research Program, unrelated to this work. Walton reports support from ICER for work on this economic model and unrelated consulting fees from Baxter.Keywords
This publication has 14 references indexed in Scilit:
- Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort studyThe Lancet, 2018
- Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophyNeurology, 2016
- Health related quality of life in European adults with DMD: Results from the Care-NMD-projectNeuromuscular Disorders, 2015
- Corticosteroid Treatments in Males With Duchenne Muscular DystrophyJournal of Child Neurology, 2014
- Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trialsEuropean Journal of Paediatric Neurology, 2012
- Evidence‐based path to newborn screening for duchenne muscular dystrophyAnnals of Neurology, 2012
- Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)The Journal of Pediatrics, 2009
- Trends in survival from muscular dystrophy in England and Wales and impact on respiratory servicesRespiratory Medicine, 2006
- A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophyMuscle & Nerve, 2000
- Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's or Becker's Muscular DystrophyThe New England Journal of Medicine, 1988